Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial
| Autor: | David Cassiman, Ger H. Koek, Cees Th B. M. van Deursen, Annick Vanclooster, Reggy Jaspers |
|---|---|
| Přispěvatelé: | Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health, RS: NUTRIM - R2 - Gut-liver homeostasis |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Population Placebo-controlled study Proton-pump inhibitor Placebo Gastroenterology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine education Pantoprazole education.field_of_study HEREDITARY HEMOCHROMATOSIS Hepatology business.industry IRON Proton Pump Inhibitors Phlebotomy Surgery 030220 oncology & carcinogenesis Hereditary hemochromatosis Randomized Clinical Trial 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Gastroenterology, 153(3), 678-680.e2. Elsevier Saunders |
| ISSN: | 0016-5085 |
| Popis: | Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performed when serum ferritin was > 100 μg/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy. Clinicaltrials.gov: NCT01524757. ispartof: Gastroenterology vol:153 issue:3 pages:678-680 ispartof: location:United States status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|